中经记者 晏国文 卢志坤 北京报道 2025年12月10日，由《中国经营报》主办的"大重构·大机遇——2025中国医药大健康产业论坛"在北京 隆重召开。 在会上，安科生物（300009.SZ）执行总裁姚建平以"创新引领企业高质量发展"为主题进行了演讲。姚 建平介绍，经过多年的发展，安科生物已经形成了以生物医药为主轴，以中西药物、精准医疗为两翼， 同时积极布局mRNA技术、ADC、溶瘤病毒、细胞治疗、基因治疗等领域，形成了"一主两翼"协同发展 的战略布局。 "百亿安科，百年安科"是安科生物的战略发展目标。姚建平介绍，"百亿"有三个含义：市值百亿元、营 收百亿元、利润百亿元。 据了解，安科生物是中国最早的生物制药公司之一，是2009年首批在创业板上市的公司之一。 安科生物的第一个创新是机制创新，并且创新始于企业成立之初。姚建平介绍："安科生物成立之初是 一家国有企业，由中国科技大学和安徽省生物研究所各占50%的股权。在20世纪90年代中后期，市场经 济时代逐渐拉开帷幕，国有体制改革在艰难中前行。安科生物分别在1995年、1996年和2000年进行过三 次股份制改制。" 自成立以来，安科生物一直以创新为引领，在产品 ...

中经记者 晏国文 卢志坤 北京报道 （安科生物执行总裁姚建平作主题演讲。） 2025年12月10日，由《中国经营报》主办的"大重构 大机遇"2025中国医药大健康产业论坛在北京隆重 召开。 在会上，安科生物（300009.SZ）执行总裁姚建平以"创新引领企业高质量发展"为主题进行了演讲。姚 建平介绍，经过多年的发展，安科生物已经形成了以生物医药为主轴，以中西药物、精准医疗为两翼， 同时积极布局mRNA技术、ADC、溶瘤病毒、细胞治疗、基因治疗等领域，形成了"一主两翼"协同发展 的战略布局。 "百亿安科，百年安科"是安科生物的战略发展目标。姚建平介绍，"百亿"有三个含义：市值百亿元、营 收百亿元、利润百亿元。 据了解，安科生物是中国最早的生物制药公司之一，是2009年首批在创业板上市的公司之一。 在演讲中，姚建平还提到AI与医药研发的结合。"AI+生物技术、生物医药怎么去结合？其实是完全可 以结合的，比如在药物的大分子设计、药物临床前研究的方案设计、临床研究过程中，包括整个临床方 案的推动……都可以用大数据做一些支撑。一个多肽分子或者一个生物大分子，通过AI来设计，可以 大大缩短它的发现时间，可能会从原来的5年 ...

Financial Performance - In Q3 2025, the company achieved a revenue of CNY 670 million, a year-on-year increase of 7.70%, and a net profit of CNY 185 million, up by 6.56% [3] - For the first nine months of 2025, the company reported a revenue of CNY 1.963 billion, a year-on-year growth of 2.15%, while net profit decreased by 6.48% to CNY 551 million [3] - The growth in Q3 revenue and net profit was primarily driven by increased sales of growth hormones and antibody drugs [3] Product Development and Clinical Trials - The PA3-17 injection from the company's affiliate, Boshengji, is in Phase II clinical trials and aims for conditional market approval [3] - The "AK2017 injection" (recombinant human growth hormone-Fc fusion protein) has completed Phase II clinical trial enrollment and is expected to start Phase III trials in early 2026 [4] - The "HuA21 injection," targeting HER2, showed an objective response rate (ORR) of 80.8% in the 30 mg/kg group during exploratory studies [5] - The "HK010 injection" (PD-L1*4-1BB) is in Phase I clinical trials, showing good efficacy and safety in various cancers [9] Market Strategy and Future Outlook - The company plans to enhance operational efficiency and solidify the growth of its core business while accelerating the development of other business areas [3] - The collaboration with Weisheng Pharmaceutical on the long-acting growth hormone aims to penetrate the high-end market, enhancing product visibility and sales [4] - The company anticipates a market size exceeding CNY 4 billion for follicle-stimulating hormone in 2025, with plans to capture significant market share [10] - Sales and R&D expenses are expected to increase slightly over the next two years due to the rise in innovative drug trials and new product launches [11] Strategic Initiatives - The company has established an innovation research institution in Shanghai to support the development of self-researched and commercially cooperative products [12] - Plans for expanding production capacity include new production lines in northern and eastern regions, expected to contribute to economic growth [12]

Core Viewpoint - Anhui Anke Biotechnology (Group) Co., Ltd. is focusing on optimizing sales channels and strategies to enhance market development amidst industry competition and market fluctuations, with plans for further business growth in the second half of 2025 [2][4]. Group 1: Financial Performance - In the first half of 2025, Anhui Anke Biotechnology achieved operating revenue of 1,292.19 million yuan, a year-on-year decrease of 0.51% [2]. - The parent company reported operating revenue of 910.31 million yuan, an increase of 5.13% year-on-year [2]. - Net profit was 374.55 million yuan, down 11.61% year-on-year, while net profit attributable to shareholders was 366.52 million yuan, a decrease of 11.92% [2]. - The net cash flow from operating activities was 316.42 million yuan, reflecting a significant increase of 53.75% year-on-year [2]. Group 2: Business Development and Strategy - The main business segment of biological products reversed the downward trend with a year-on-year growth of 7.49%, and sales revenue of the injection drug Trastuzumab "Ansaiting" surged by 298% [2]. - The company is enhancing its product matrix through external collaborations and strengthening its R&D and talent team to improve competitiveness and solidify its industry position [4]. Group 3: Growth Hormone Segment Insights - In the first half of 2025, the new patient enrollment for growth hormone remained stable year-on-year, with water injections accounting for over 40% of the market [3]. - The long-acting growth hormone "Longpei Growth Factor," developed in collaboration with Weisheng Pharmaceutical, is expected to be approved in the second half of 2025, targeting the high-end market [3]. - The product boasts advantages such as good safety, high effectiveness, strong stability, and convenience, with an innovative auto-injector requiring only weekly administration [3]. Group 4: R&D Pipeline and Future Plans - The company has multiple self-developed innovative drug projects entering the registration stage, including "HuA21 Injection" and "AK2024 Injection" [3]. - Collaborations with companies like Afana and Boshengji are progressing, with a focus on breakthrough treatment varieties and clinical trials [3]. - The company plans to slightly increase sales and R&D expenses in the next two years as innovative drug clinical trials and product launches ramp up [3].

Group 1: Company Strategy and Goals - The overall business goal for 2025 is to achieve restorative growth and maintain stable development [3] - The company aims to enhance the sales proportion of growth hormone water injections and expand the indications for growth hormone [3] - The company plans to accelerate the production capacity of the cancer drug Trastuzumab (Ansatin) and deepen brand building and market expansion [3] Group 2: Product Development and Clinical Trials - The clinical trial for "AK2017 Injection" (recombinant human growth hormone-Fc fusion protein injection) has successfully completed Phase II enrollment, with discussions for Phase III trial already held [3] - The company is actively promoting clinical trials for interferon spray and inhalation agents, targeting respiratory infections and gynecological diseases [3] - The "AK1008 Project" (human interferon α2b spray) is in Phase II trials for treating viral infections in children [3] Group 3: Competitive Landscape - Currently, there are 5 companies producing short-acting growth hormones, and several companies are expected to launch long-acting growth hormones [4] - The market for growth hormones is competitive but the overall pricing system remains stable [4] - The strategic partnership with Weisheng Pharmaceutical aims to cover the long-acting growth hormone market and enhance the company's competitiveness in children's growth and development [7] Group 4: Innovation and Collaborations - The company is developing several innovative drugs, including "HuA21 Injection" targeting HER2, which has shown promising safety and efficacy in early trials [4] - Collaboration with Afana Company on "AFN0328 Injection" for HPV precancerous lesions is in Phase I trials, with plans for further mRNA drug development [5] - The company is also involved in CAR-T cell therapy research through its investment in Boshengji Company, which has received implicit approval for clinical trials [5] Group 5: Market Expansion and Future Plans - The company is preparing to expand its international market presence by building FDA and EU-compliant production lines and engaging with foreign distributors [8] - The exclusive agency agreement with Baoji Pharmaceutical for the innovative drug "SJ02" aims to enhance the company's product matrix in the assisted reproduction field [8] - The company anticipates that the launch of long-acting growth hormones and long-acting follicle-stimulating hormones will provide new growth points for its business [8]

Group 1: Financial Performance and Challenges - In 2024, the company experienced its first decline in revenue and net profit, primarily due to decreased sales in its main business segments, including bioproducts and traditional Chinese medicine [2][3] - The company aims for recovery growth in 2025, focusing on enhancing academic promotion and increasing the sales proportion of its water injection products [3] - The sales of "Ansaiting" are expected to show significant year-on-year growth in 2025, while the traditional Chinese medicine segment has resumed production and aims to maintain growth [3] Group 2: Research and Development (R&D) Strategy - The decline in R&D expenditure does not indicate a reduction in R&D efforts; rather, it reflects the clinical product structure and progress at different times [5] - The company is advancing its R&D capabilities and is involved in innovative technology investments, with a focus on clinical trial phases [5] - Future R&D investments are expected to increase as products like "AK2017 Injection" progress to Phase III clinical trials [5] Group 3: Market Expansion and Product Development - The company is actively building production lines compliant with FDA and EU certifications to facilitate overseas market entry [6] - AI technology is being utilized to assist in drug development, including molecular design and data integration for various business applications [8] - The company is developing new formulations of interferon for respiratory infections and gynecological diseases, with ongoing clinical trials for several products [9] Group 4: Clinical Pipeline Overview - The company has several products in clinical trials, including "HuA21 Injection" for HER2-targeted therapy, which has completed Phase Ib/II trials and is preparing for Phase III [10][11] - "AK2017 Injection" (recombinant human growth hormone-Fc fusion protein) is progressing well in clinical trials, having completed Phase II and moving towards Phase III [11] - The company is also exploring new indications for growth hormone and accelerating the development of tumor drugs like "Ansaiting" [9][11]

Group 1 - Arvinas and Pfizer submitted a New Drug Application (NDA) for Vepdegestrant, the first PROTAC drug to seek approval, targeting advanced or metastatic breast cancer patients with ESR1 mutations [1] - The approval of Vepdegestrant could fill a significant treatment gap in the breast cancer market, attracting substantial investment and enhancing the overall industry valuation [1] Group 2 - Beijing Tide Pharmaceutical's TDI01 has been proposed for inclusion as a breakthrough therapy for chronic graft-versus-host disease (cGVHD), indicating its potential in a complex treatment area [2] - TDI01 is a novel ROCK2 inhibitor, and its breakthrough designation could significantly enhance the company's valuation and attract investor interest, bolstering China's innovative drug competitiveness [2] Group 3 - Anke Biotech anticipates significant sales growth for its trastuzumab product, Ansaiting, projecting over 100 million yuan in revenue for 2024 [3] - The positive market performance of Ansaiting enhances Anke Biotech's position in the oncology sector, potentially attracting more investors and supporting future research and market expansion [3] Group 4 - Haiwang Bio announced the termination of its control change and stock issuance, indicating ongoing discussions with state-owned entities for potential equity cooperation [4] - The proactive approach to resource integration and business collaboration may create new growth opportunities for Haiwang Bio, positively influencing market perceptions of its long-term value [4] Group 5 - Green Valley Pharmaceutical has ceased production of its Alzheimer's drug, Ganluo Sodium Capsules, following concerns over its efficacy and safety [6] - The shutdown reflects significant operational adjustments for the company, potentially leading to investor concerns about its future prospects and market confidence [6]